drugset / Trial / NCT00853983

Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers

NCT00853983

Phase 1 Completed 6 enrolled AstraZeneca
NaSingle-groupOpen-labelBasic science

Summary

The aim of this study is to show how the body absorbs, metabolises and excretes the drug \[14C\]AZD0530. As for all clinical trials, safety and tolerability of the drug will be evaluated.

Timeline

Start
2009-03
Primary completion
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject saracatinib Small molecule Oral

Indications

No indication recorded.